June 2, 2009 – Nucletron BV, a cancer radiation solutions company, has created of an exclusive partnership and plans to merge with sector peer Isodose Control BV for an undisclosed sum.
The two companies, headquartered in Veenendaal and Ede, the Netherlands, are complementary and the combination will strengthen Nucletron’s position as a global leader in the market for high-precision radiation therapy equipment and software for brachytherapy.
The merger plans were announced by the two companies’ CEOs June 1 in Toronto, Canada, at the American Brachytherapy Society’s annual conference.
“By combining strengths we will become the undisputed global market leader in brachytherapy, which offers quality, safe and effective treatment options for the most frequently occurring kinds of cancer,’’ said Jos Lamers, CEO of Nucletron.
Nucletron is the world’s number one medical equipment provider in the brachytherapy market, with a strong focus on customer support; Isodose Control has grown in six years to become number three and has an impressive product innovation track record.
“Isodose Control has developed a range of innovative brachytherapy products and has a promising range in development. Together with Nucletron, we look forward to speeding up the market introductions of these innovations to healthcare institutions and their patients worldwide,” said Eric van’t Hooft, CEO of Isodose Control BV.
Nucletron reported EBITDA of € 17 million on net sales of € 112.4 million in 2008.
For more information: www.nucletron.com
July 11, 2024 
